Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saffron Total-glycoside Tablet for cardioprotection in anthracycline-treated breast cancer
ChiCTR2000041134Phase 4Not yet recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in breast cancer, heart failure (HF) and Cardiotoxicity comparing Saffron Total-glycoside Tablet with Placebo (2 arms). Primary endpoint: Prevention of systolic dysfunction. Planned start May 2021; status: not yet recruiting.
02
Drugs
saffron total-glycoside
03
Conditions
breast cancerheart failure (HF)Cardiotoxicity
Beyond the preview
Go deeper on ChiCTR2000041134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041134.